YSOPIA Bioscience leading biotech in the development of innovative microbiome-based therapies

YSOPIA Bioscience, a leading biotech in next-generation microbiome-based biotherapies that harness the power of keystone single-strain bacteria

more +
lnc
Our Story

Our team is committed to deliver groundbreaking therapeutic solutions to patients with high needs

more +
lnc
therapeutic solutions
lnc

YSOPIA Bioscience is the 1st company to harness the therapeutic potential of Christensenella

Our leadership

Fabrice GUEZ
Fabrice GUEZ CEO & CFO
Fabrice GUEZ
CEO & CFO

Putting people first

Fabrice is an accomplished executive with more than two decades of experience within biotech environment and pharmaceutical SMEs. He co-founded YSOPIA Bioscience.

Sandrine CLAUS
Sandrine CLAUS CSO
Sandrine CLAUS
CSO

Beyond the state of the art

Sandrine joined YSOPIA Bioscience in 2017 as Chief Scientific Officer. She previously served as Associate Professor in Integrative Metabolism at the University of Reading’s department of Food and Nutritional Sciences.

Frédéric Elustondo
Frédéric Elustondo Senior Director of Operations
Frédéric Elustondo
Senior Director of Operations

Execute the right project

Frederic’s expertise focuses on project management and innovation in the different positions he held in the hospital & health care industry.

 
Marion Soto
Marion Soto Director of Business Development
Marion Soto
Director of Business Development

A growth mindset

Marion joined YSOPIA Bioscience in 2017. She currently leads the business development and pipeline strategy of the Company, as well as the IP strategy.

Leveraging partnership for success more +
ICAN
LuinaBio
INRA
Quay Pharma
Cornel University
Bioaster
lnc
Where
to meet us
Obesity Week, November 1-5
> more
Journées Polepharma de Microbiomique – 2ème édition, November 4-5
> more
Microbiome Connect: Gut Therapeutics EU, December 7-8
> more
Microbiome & us
News
Jan 20, 2022
Alliance Promotion Microbiote devient une Association et poursuit la structuration de la filière française du...
> more
Dec 2, 2021
YSOPIA Bioscience Announces First Signs of Biological Activity from Phase I Analysis of Xla1, its Biotherapy Targeting...
> more
Press / Media
Dec 3, 2021
Access the full article  
> more
Dec 3, 2021
YSOPIA Bioscience annonce des premiers signes d’activité biologique suite à l’analyse des résultats de l’étude...
> more
Publications
Nov 1, 2021
We are pleased to present our poster highlighting safety and first efficacy results of our Xla1 biotherapy targeting...
> more
Sep 1, 2021
Héloïse Tudela, Sandrine P. Claus and Maya Saleh Access the full paper The community of the diverse microorganisms...
> more
now on twitter
YSOPIA Bioscience

On January 26th - 1,50pm, our CSO Sandrine Claus will be presenting the results of our latest research on Christens… t.co/FD0xMEojxr

YSOPIA Bioscience © 2022 - all rights reserved terms and conditions Influa | Web Agency © 2018